The Carlat Psychiatry Podcast

The Carlat Psychiatry Podcast

A New Option for Bipolar Depression

January 24, 2022

Lumateperone (Caplyta) just got FDA approved for bipolar depression. Find out how it compares to other atypical antipsychotics.

CME: Take the CME Post-Test For This Episode

Published On: 01/24/2022

Duration: 24 minutes, 09 seconds

Chris Aiken, MD, and Kellie Newsome, PMHNP, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Got feedback? Take the podcast survey.